medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination

Anne Hege Aamodt[1,2], Thor Ueland[3,4,5], Marion I. Boldingh[1], Burcu Bezgal[1], Maria Argren[1,4], Cecilia Adele Dunne[4], Kari Otterdal[3], Ida Gregersen[3], Vigdis Bjerkeli[3,4], Annika Elisabet Michelsen[3,4], Andreas Husøy[2,6], Åse Hagen Morsund[7], Kristina Devik[1,8], Anne Christine Poole[9], Kristine Gjendemsjø[10], Katrin Schlüter[11], Sara Maria Mathisen[11], Mari Aalstad-Johansen[12], Thor Skattør[1,4,13], Julie Sønnervik[14], Birgitte Boye[15,16], Trine Haug Popperud[1], Einar August Høgestøl[1,4], Hanne Flinstad Harbo[1,4], Fridtjof Lund-Johansen[4,17], Pål Aukrust[3,4,18], Erling Tronvik[2,6], Tuva Børresdatter Dahl[3], Bente E. Halvorsen[3,4,19]

[1]Department of Neurology, Oslo University Hospital, Oslo, Norway
[2]Department of Neuromedicine and Movement Science, the Norwegian University of Science and Technology, Trondheim, Norway
[3]Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
[4]Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
[5]Thrombosis Research Center (TREC), Division of internal medicine, University Hospital of North Norway, Tromsø, Norway
[6]Department of Neurology of Clinical Neurophysiology, St. Olav Hospital, Trondheim, Norway
[7]Department of Neurology, Molde Hospital, Molde, Norway
[8]Department of Neurology, Namsos Hospital, Molde, Norway
[9]Oslo Headache Centre, Oslo, Norway
[10]Sandvika Neuro Centre, Sandvika, Norway
[11]Department of Neurology, Stavanger University Hospital, Stavanger, Norway
[12]Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway
[13]Department of Radiology, Oslo University Hospital, Oslo, Norway
[14]Hodeverket, Sandnes, Norway
[15]Unit Psychosomatic medicine and CL psychiatry, Oslo University Hospital, Oslo, Norway
[16]Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
[17]Department of Immunology, Oslo University Hospital, Oslo, Norway.
[18]Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway
[19]Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Background and objectives: New onset persistent headache has been reported following acute COVID-19 disease and to some degree also after SARS-CoV-2 vaccination. Still, the mechanisms for these headache types are unclear. The purpose of this study was to assess levels of amyloid related biomarkers in patients with persistent headache after COVID-19 and SARS-CoV-2 vaccine.

Methods: In this prospective observational cohort, patients with severe headache as the dominating symptom after COVID-19 disease (n=29) and SARS-CoV-2 vaccination (n=31), had neurological assessments with reassessments after 6 months. Plasma levels of amyloid precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL) and serum Amyloid A (SAA1) were measured by ELISA in relation to levels in healthy controls (n=16).

Results: We found a strong and persistent upregulation of APP in patients with headache after COVID-19 as compared to the two other groups. At both inclusion and after 6 months APP levels were also increased in those with accompanying cognitive symptoms. In contrast, plasma levels of PZP were elevated in both headache groups as compared to healthy controls at inclusion and after 6 months follow-up, but with no relation to cognitive symptoms. CTSL was only elevated in those with COVID-19 associated headache at baseline, whereas SAA1 showed levels comparable in all groups.

Conclusion: Altered plasma levels of soluble markers potentially reflecting changes in amyloid processing was found in patients with persistent headache after SARS-CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease where we also found some association with cognitive symptoms.

NCT04576351

NCT05235776

What is already known on this topic

New onset persistent headache occurs in a subset of individuals after COVID-19 and to some extent after SARS-CoV-2 vaccine. However, the pathophysiological mechanisms are unknown.

What this study adds

There was high disability with only modest improvement after 6-month follow-up.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Altered plasma levels of soluble markers that potentially could reflect changes in amyloid processing was found in patients with persistent headache after SARS-CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease with association to cognitive symptoms.

How this study might affect research, practice or policy

Our data point to plausible mechanism of amyloid processing and neuroinflammation in relation to COVID-19 and SARS-CoV-2 vaccine.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction

During the COVID-19 pandemic, headache emerged as an important health issue, increasing the burden of headache disorders.[1, 2] Both SARS-CoV-2 infection and, although to a lesser degree, SARS-CoV-2 vaccination, induced headache as a secondary headache disorder as well as negatively impact already existing primary headache disorder.[1, 3] Thus, those with primary headache disorder experience headache in the acute phase of COVID-19 and after vaccination more often than other SARS-CoV-2-infected or vaccinated individuals.[1] Approximately one in five patients who present headache during the acute phase of COVID-19, get persistent headache, often with accompanying symptoms including cognitive symptoms and fatigue.[1] Also, a subset of individuals with headache attributed to SARS-CoV-2 vaccinations develop long lasting headaches.[1, 3] Furthermore, in patients with primary headache disorders, SARS-CoV-2 vaccination and in particular an acute SARS-CoV-2 infection worsened their chronic headache burden.[3] The mechanisms for persistent headaches after SARS-CoV-2 infection or vaccines are, however, unknown. One proposed mechanism is persistent immune activation and inflammation triggered by SARS-CoV-2 or vaccination.[4, 5] with the trigeminovascular system as a potential target.[1] Additionally, the inflammatory responses during acute COVID-19 disease, involving the release of prostaglandins, interleukin (IL)-6 and other inflammatory cytokines could increase blood-brain barrier permeability leading to neuroinflammation with accompanying headache.[6, 7]

Serum Amyloid A (SAA1), an acute phase protein and systemic marker of inflammation, was early reported as a biomarker of poor prognosis in COVID-19.[8] Recently, amyloid precursor protein (APP), a membrane protein considered to play a main role in Alzheimer disease pathology,[9] was described as a new receptor for SARS-CoV-2 infection and revealed a previously unknown mechanistic insight into COVID-19 related neuropathological sequelae.[10] Moreover, Pregnancy Zone Protein (PZP), originally known as a broad-spectrum immune-suppressive protein that suppresses T-cell function during pregnancy to prevent foetal rejection, has also been proposed as a biomarker for various inflammatory disorders,[11, 12] including the prognosis of COVID-19 disease.[13] With relevance to CNS involvement, serum levels of PZP were higher in women with pre-symptomatic Alzheimer's disease.[14] Furthermore, Cathepsin L1 (CTSL), a lysosomal cysteine protease that plays a major role in intracellular protein catabolism, has been demonstrated to enhance SARS-CoV-2 virus entry, at least in pre-clinical models,[15] and interestingly, CTSL has also been suggested to be involved in the degradation of certain amyloid fibrils.[16] To this end, however, circulating levels of these biomarkers (i.e., SAA1, APP, PZP, and CTSL) in patients

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

with persistent headaches after SARS-CoV-2 infection or vaccination, with or without headache during the acute phase of COVID-19 or immediately after vaccination, have not been reported.

In the present study, with the aim to give novel insight into the pathological mechanisms leading to persistent headache following COVID-19 and SARS-CoV-2 vaccination, we compared plasma levels of APP, PZP, CTSL, and SAA-1 in patients with persistent headache after SARS-CoV-2 infection or vaccination compared with levels in healthy controls without headaches. The levels of these molecules were also related to the presence of accompanying fatigue or cognitive symptoms, and in the COVID-19 group, the need for hospitalization during the acute infection.

Methods

In this prospective observational cohort study performed at Norwegian neurological departments and led by Oslo University Hospital, Oslo, Norway, clinical characteristics and blood biomarker profiles were assessed in patients with severe headaches for a minimum of six months after COVID-19 or SARS-CoV-2 vaccination and compared to healthy controls. The inclusion period lasted from September 2020 to June 2023.

Study population and clinical assessments of the participants

The subgroup with **persistent headache after COVID-19 (n=29)** was recruited from the cohort of 155 individuals aged ≥ 18 years with persistent neurological symptoms 6 months after COVID-19 infection in the Norwegian observational multicentre study of nervous system manifestations and sequelae after COVID infection (NNC), a sub study of the ENERGY study led by European Academy of Neurology.[17] The subgroup with **persistent headache after SARS-CoV-2 vaccine** (n=31) were participants in the Norwegian observational multi-centre study CovaxHEAD: New-onset severe headache after COVID-19 vaccine (NCT05235776) - a parallel study led by the same team as the NNC study collecting comparable variables.

Inclusion criteria for both subgroups were age ≥ 18 years and new onset severe headache or severe worsening of pre-existing headache within one week after SARS-CoV-2 infection or vaccination. The degree of headache severity had to be so pronounced that the headaches were daily or almost daily and had resulted in significant disability or sick leave and still were the dominant symptom at 6-month follow-up. Exclusion criteria were short-lasting headaches, no follow-up assessments, or where other diagnoses were considered a

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

better explanation for their symptoms (e.g. infections including COVID-19, head trauma, or somatoform disorders). Participants with COVID-19 disease who reported their headaches starting after SARS-CoV-2 vaccination were not included. Thus, none in this COVID-19 subgroup had SARS-CoV-2 vaccine induced headache.

For both headache groups, an inclusion criterion was available plasma samples that could be used in biomarker analyses. The clinical data, including the headache diagnoses, were reviewed by a senior neurologist with headache expertise (AHA).

The **control group** consisted of healthy individuals (n=16) based on disease history without migraine or any other disabling headache disorders and who had never experienced neurological symptoms after SARS-CoV-2 vaccine or COVID-19. Additional inclusion criteria in the control group were no immunological disorders or use of immunosuppressive drugs. The healthy controls, consisting of 8 men and 8 women, mean age 40.6 years (SD 11.2), were recruited from local advertisements at Oslo University Hospital.

Blood sampling protocol

Peripheral venous blood was drawn into pyrogen-free blood collection tubes with ethylenediamine tetraacetic acid (EDTA) as an anticoagulant, immediately immersed in melting ice and centrifuged at 4°C 2500 × *g* for 20 minutes within 60 minutes to obtain platelet-poor plasma. The plasma samples were stored in multiple aliquots and thawed only once.

Biomarker assessments

Plasma markers were assessed in all three groups – patients with persistent headache after COVID-19 infection (n=29), patients with persistent headache after the COVID-19 vaccine (n=31), and healthy controls (n=16). The participants had blood samples drawn when they were included in the study. Additionally, 6-month follow-up blood sampling was done in the headache groups. Plasma levels of APP (Cat# DY850), PZP (Cat# DY8280-05), CTSL (Cat# DY952), and SAA1 (Cat# DY3019-05) were measured by enzyme-linked immunosorbent assay (ELISA) using commercially available antibodies (R&D Systems, Minneapolis, MN) in a 384-format using a combination of a SELMA pipetting robot (Analytik Jena AG, Jena, Germany) and a BioTek dispenser/washer (BioTek Instruments, Winooski, VT). Absorption was read at 450 nm by using an EIA plate reader (BioTek Instruments) with wavelength correction set to 540 nm. Intra- and inter-assay coefficients of variation for these analyses were all <10%.

Ethics approval

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

This study was conducted in accordance with the Helsinki Declaration as revised in 2013. Ethical approval for this study was obtained from The Norwegian South-Eastern Ethical Committee (152727 NNC, 351097 CovaxHEAD). Written informed consent was obtained from all subjects before inclusion into the study.

Statistics

Statistical Package for Social Science (IBM SPSS Inc., version 29 for Windows) was used for statistical analysis. Differences in patient characteristics were tested using the Chi-square test or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous variables. Prevalence of characteristics (frequency and percentages) were calculated for each group. A two-sided p-value of <0.05 was deemed statistically significant.

Results

Characteristics and headache phenotypes in the study group

Demographics such as age, gender and co-morbidities are shown in Table 1. There was equal age and sex distribution in both headache groups (i.e., persistent headache following COVID-19 or SARS-CoV-2 vaccination, respectively) with 3 out of 4 participants being female. Comorbidity of frequent diseases, such as pre-existing migraine, allergies, anxiety, and depression were common in both groups. Few had cardiovascular or metabolic disorders. One-third of the patients with persistent headache after COVID-19 infection was hospitalised in the acute phase of the infection. In the group with a persistent headache after SARS-CoV-2 vaccine 17 (54.8%) reported previous COVID-19 at baseline, but importantly, without any persistent headache after the infection (Table 1). There was a high disability among the participants of both headache groups. More than two thirds of the participants with post COVID-19 and more than half the participants with headache post SARS-CoV-2 vaccination were on sick-leave due to the current symptoms at inclusion with only a modest reduction in the percentages on sick-leave at 6-month follow-up (72.4 % to 65.5 % and 58.1 % to 45.2 %, post COVID-19 and SARS-CoV-2 vaccination, respectively; Table 1). Cognitive symptoms and fatigue were common, but not dominating (see Methods), in both headache groups (Table 1).

Table 1. Demographic and clinical characteristics at inclusion

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Characteristics	Headaches after COVID-19 n = 29	Headaches SARS-CoV-2 vaccine n = 31	P value
Mean age at inclusion, (SD)	43.5 (11.2)	43.8 (12.4)	0.836
Female, n (%)	22 (75.9)	24 (77.4)	0.862
Education			
Secondary school n (%)	2 (6.8)	7 (22.6)	0.193
College/university ≤ 4 years, n (%)	14 (48.3)	12 (38.7)	
College/university > 4 years, n (%)	13 (44.8)	12 (38.7)	
Hospitalisation during COVID-19, n (%)	9 (31.0)	3 (9.7)	
Smoking, n (%)	1 (4.4)	2 (6.5)	0.610
Pre-existing migraine, n (%)	11 (31.0)	12 (38.7)	0.871
Comorbidities			
Allergy, n (%)	16 (55.1)	13 (41.9)	0.240
Asthma, n (%)	2 (6.9)	6 (19.4)	0.150
Depression, n (%)	8 (27.6)	10 (32.3)	0.759
Anxiety, n (%)	7 (24.1)	13 (41.9)	0.170
Diabetes, n (%)	0	1 (3.3)	0.330
Cardiovascular disease, n (%)	0	1 (3.3)	0.330
Stroke, n (%)	0	0	
Associated symptoms			
Fatigue, n (%)	22 (75.9)	20 (64.5)	0.204
Subjective cognitive symptoms, n (%)	22 (75.9)	17 (54.8)	0.119
Sick leave at first visit, n (%)	21 (72.4)	18 (58.1)	0.244
Sick leave at 6-month follow-up, n (%)	19 (65.5)	14 (45.2)	0.207

Biomarkers in relation to post-COVID-19 headache and headache following SARS-CoV-2 vaccination

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

At both inclusion and after 6 months, we found a strong and persistent upregulation of APP in patients with headache after COVID-19 as compared to individuals with vaccine induced headache and healthy controls (Figure 1A). There was also upregulation of CTSL in patients with headache after COVID-19 as compared to individuals with vaccine induced headache and healthy controls at inclusion, but these differences were not seen at 6 months follow-up (Figure 1B). In contrast, plasma levels of PZP were elevated in both headache groups as compared to healthy controls at inclusion and after 6 months follow-up (Figure 1C). As for SAA1, being a classical acute phase protein reflecting inflammation, there were no differences between the two headache groups and healthy controls either at baseline or during follow-up (Figure 1D). Finally, whereas post-COVID-19 symptoms have been related to disease severity during the acute phase,[18] we found no differences in the actual biomarkers between those who were hospitalized and those who were not hospitalized during the acute phase of COVID-19 (data not shown).

Biomarker levels in relation to associated fatigue and cognitive symptoms

There was a significant upregulation of APP among participants with accompanying cognitive symptoms in the group with persistent headache after COVID-19, but this pattern was not seen in those with headache after SARS-CoV-2 vaccination (Figure 2). Although those with fatigue also had higher levels of APP compared with those without, the difference did not reach statistical significance (Figure 2). As for PZP, CTSL, there were no differences between those with or without associated cognitive symptoms or fatigue, neither in the COVID-19 nor the SARS-CoV-2 group (data not shown).

Discussion

Persistent headache has been reported following acute COVID-19 disease and to some degree also after SARS-CoV-2 vaccination.[1, 3] In the present study, we report higher plasma levels of APP in patients with persistent headache after COVID-19 disease, but not in patients with persistent headache following SARS-CoV-2 vaccination, compared to healthy controls. Remarkably, elevated APP persisted at 6 months follow-up and was associated with accompanying cognitive symptoms. Notably, plasma levels of PZP were higher in both headache groups as compared to controls with a similar pattern after 6 months follow-up. This is to the best of our knowledge, the first report that relates proteins involved in amyloid formation in persistent headache following COVID-19 disease, and for PZP, also in individuals with persistent headache after SARS-CoV-2 vaccination.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

As depicted in Figure 3, our data point to plausible mechanism of serum APP and PZP proteins in relation to COVID-19 and SARS-CoV-2 vaccine induced headache. In brief, APP is produced by neurons and proteolysis by different secretases may produce a soluble (s) fragment, sAPP, and release of the neurotoxic Aβ peptide. SARS-CoV-2 infection may increase APP expression via the ACE2 receptor[19, 20] and APP promotes cellular entry of the virus enhancing Aβ-associated pathology.[10] The Aβ peptide may accumulate and form amyloid plaques[21] leading to activation of astrocytes and microglia and promote neuroinflammation by different mechanisms[22] with potential effect on headache symptoms.[23]

Increased levels of APP is reported as marker for preclinical Alzheimer disease, however, this protein biological function is beyond that of amyloid formation[24] and elevated levels has been found in various metabolic and cardiovascular disorders.[25] In the present study, however, few or none had such clinically verified co-morbidities. However, we found significant upregulation of APP among participants with accompanying cognitive symptoms in the group with persistent headache after COVID-19 compared to those without cognitive symptoms. Moreover, network analyses of SARS-CoV-2 infection in brain microvascular endothelial cells suggested increased expression of APP.[19] In a previous study of patients with COVID-19 associated neurological syndromes, signs of impaired amyloid processing was found with significantly reduced soluble amyloid precursor protein in CSF from patients compared to controls.[26] However, this study was dominated of patients with severe neurological diseases such as Guillain Barre syndrome and encephalopathy and only one patient was described with central pain syndrome.[26] Furthermore, cognitive symptoms were not reported. At present, however, the reason for and the clinical consequences of the raised APP in patients with persistent headache following COVID-19 disease is elusive and follow-up studies are clearly needed.

In contrast to APP, plasma levels of PZP were persistently elevated in both headache groups, i.e., prolonged headache following both COVID-19 and SARS-CoV-2 vaccination. The reason for this pattern is so far unclear. PZP is known to promote a beneficial immunosuppression during pregnancy to avoid rejection of the foetus. More recently, increased PZP levels has been found during airway infections[12] and have been suggested as a marker of certain cancers.[27] Moreover, previous studies with mouse models have indicated that APP can increase the entry of the SARS-Cov-2 virus into cells whereas PZP has been described to inhibit amyloid aggregation.[28] Since APP was lower in the vaccine group than the COVID-19 group, one intriguing hypothesis is that PZP were able to inhibit amyloid aggregation at a higher degree in the vaccine group than in the COVID-19 group. However,

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

PZP has also been reported to stabilize misfolding proteins like amyloid β protein, and the role of PZP in amyloid formation is still not clear.[28]

The strengths of this study were the comprehensive examinations of the participants done by headache specialists with precise phenotyping of the headache syndromes and the strong multidisciplinary collaboration. The major limitations were the lack of CSF samples in both headache groups. Moreover, we lack parallel samples from CSF and measurements of the actual protein in individuals that have undergone COVID-19 and SARS-CoV-2 vaccination without the development of persistent headache.

In summary, altered plasma levels of soluble markers that potentially could reflect changes in amyloid processing was found in patients with persistent headache after SARS-CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease with association to cognitive symptoms. Future and larger studies that also include CSF samples are needed to further elaborate the clinical consequences of these findings.

Acknowledgement: We thank Marcus Boateng for registering data and Katrine Persgård Lund and Azita Rashidi for the processing of blood biomarkers.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Caronna E, van den Hoek TC, Bolay H, et al. Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review. Cephalalgia 2023;43:3331024221131337.
2. Shen Q, Joyce EE, Ebrahimi OV, et al. COVID-19 illness severity and 2-year prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and Denmark. Lancet Reg Health Eur 2023;35:100756.
3. Atalar AC, Acarli ANO, Baykan B, et al. COVID-19 vaccination-related headache showed two different clusters in the long-term course: a prospective multicenter follow-up study (COVA-Head Study). J Headache Pain 2023;24:132.
4. Files JK, Sarkar S, Fram TR, et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 2021;6.
5. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591:639-644.
6. Garces KN, Cocores AN, Goadsby PJ, Monteith TS. Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting. Curr Pain Headache Rep 2022;26:895-918.
7. Hervé CL, B.; Del Giudice, G.; Didierlaurent, AM.; Tavares Da Silva, F. . The how's and what's of vaccine reactogenicity. NPJ Vaccines 2019;4.
8. Li HX, X.; Ren, H.; Xu, L.; Zhao, L.; Chen, X.; Long, H.; Wang, Q.; Wua, Q. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect 2020;80:646–655.
9. Orobets KS, Karamyshev AL. Amyloid Precursor Protein and Alzheimer's Disease. Int J Mol Sci 2023;24.
10. Chen J, Chen J, Lei Z, et al. Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid-beta-associated pathology in APP/PS1 mouse model of Alzheimer's disease. Transl Psychiatry 2023;13:396.
11. Shao J, Jin Y, Shao C, Fan H, Wang X, Yang G. Serum exosomal pregnancy zone protein as a promising biomarker in inflammatory bowel disease. Cell Mol Biol Lett 2021;26:36.
12. Finch S, Shoemark A, Dicker AJ, et al. Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. Am J Respir Crit Care Med 2019;200:992-1001.
13. Villar M, Urra JM, Rodriguez-Del-Rio FJ, et al. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology. Front Immunol 2021;12:730710.
14. Ijsselstijn L, Dekker LJ, Stingl C, et al. Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. J Proteome Res 2011;10:4902-4910.
15. Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther 2021;6:134.
16. Wang H, Sang N, Zhang C, Raghupathi R, Tanzi RE, Saunders A. Cathepsin L Mediates the Degradation of Novel APP C-Terminal Fragments. Biochemistry 2015;54:2806-2816.
17. Beghi E, Moro E, Davidescu EI, et al. Comparative features and outcomes of major neurological complications of COVID-19. Eur J Neurol 2023;30:413-433.
18. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

19. Camacho RC, Alabed S, Zhou H, Chang SL. Network Meta-analysis on the Changes of Amyloid Precursor Protein Expression Following SARS-CoV-2 Infection. J Neuroimmune Pharmacol 2021;16:756-769.
20. Caradonna A, Patel T, Toleska M, Alabed S, Chang SL. Meta-Analysis of APP Expression Modulated by SARS-CoV-2 Infection via the ACE2 Receptor. Int J Mol Sci 2022;23.
21. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011;34:185-204.
22. Di Benedetto G, Burgaletto C, Bellanca CM, Munafo A, Bernardini R, Cantarella G. Role of Microglia and Astrocytes in Alzheimer's Disease: From Neuroinflammation to Ca(2+) Homeostasis Dysregulation. Cells 2022;11.
23. Kursun O, Yemisci M, van den Maagdenberg A, Karatas H. Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain 2021;22:55.
24. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 2006;1:5.
25. Guo Y, Wang Q, Chen S, Xu C. Functions of amyloid precursor protein in metabolic diseases. Metabolism 2021;115:154454.
26. Ziff OJ, Ashton NJ, Mehta PR, et al. Amyloid processing in COVID-19-associated neurological syndromes. J Neurochem 2022;161:146-157.
27. Huang J, Xu Y, Chen Y, et al. Revisiting the role of pregnancy zone protein (PZP) as a cancer biomarker in the immunotherapy era. J Transl Med 2024;22:500.
28. Cater JH, Kumita JR, Zeineddine Abdallah R, et al. Human pregnancy zone protein stabilizes misfolded proteins including preeclampsia- and Alzheimer's-associated amyloid beta peptide. Proc Natl Acad Sci U S A 2019;116:6101-6110.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure legends

Figure 1. Plasma levels of **A.** Amyloid Precursor Protein (APP), **B**. Cathepsin L., **C.** Pregnancy Zone Protein (PZP) and **D**. Serum Amyloid A (SAA1) in healthy controls (HC) (n=16), participants with persistent headache after SarsCoV-2 vaccine (COvax) (n=31) and participants with persistent headache after COVID-19 (C19) (n=29).

Figure 2. Plasma levels of Amyloid Precursor Protein (AAP) in relation to cognitive symptoms and fatigue in those with persistent headache after SARS-CoV-2 vaccine (COvax) or COVID-19 (C19).

Figure 3. Possible mechanisms of soluble Amyloid Precursor Protein (sAPP) and Pregnancy Zone Protein (PZP) in relation to COVID-19 and SARS-CoV-2 vaccination associated headache. The authors wish to acknowledge SERVIER Medical Art (www.servier.fr) for use of their medical art kits when making the illustration in the article.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Study funding: Supported by Oslo University Hospital and the Southern and Eastern Norway Regional Health Authority (2021051).

Acknowledgement: We thank Marcus Boateng for registering data and Katrine Persgård Lund and Azita Rashidi with the sampling of blood biomarkers.

Statistical Analysis: Thor Ueland and Anne Hege Aamodt

Disclosure

Conflicts of interest: The authors report no disclosures relevant to this study.

A.H. Aamodt has received honoraria for advice or lecturing from Pfizer Allergan, Teva, Novartis, Roche, Lundbeck and Teva and research grant from Boehringer Ingelheim.

Anne Christine Poole: lecturing, advisory boards and/or clinical studies: Abbvie, Lundbeck, Pfizer, Novartis, Teva, Eli Lilly

Co-investigators	Affiliations
Øyvind Torkildsen	Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway
Vojetch Novotny	Department of Neurology, Haukeland University Hospital, Bergen, Norway
Heidi Øyen Flemmen	Department of Neurology, Telemark Hospital Trust, Skien, Norway
Hilde Karen Ofte	Department of Neurology, Nordlandssykehuset, Bodø, Norway
Christian Samsonsen	Department of Neurology of Clinical Neurophysiology, St. Olav Hospital, Trondheim, Norway
Barbara Ratajczak-Tretel	Department of Neurology, Østfold Hospital Trust, Sarpsborg, Norway
Anette Huuse Farmen	Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway
Per Selnes	Department of Neurology, Akershus University Hospital, Nordbyhagen, Norway and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Stein Andersson	Department of Psychology, University of Oslo, Oslo, Norway
Erlend Bøen	Unit for Psychosomatics and C-L psychiatry for adults, Oslo University Hospital, Oslo, Norway

medRxiv preprint doi: https://doi.org/10.1101/2024.10.19.24315794; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Siv Elin Pignatiello	Unit for Psychosomatics and C-L psychiatry for adults, Oslo University Hospital, Oslo, Norway and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway


A
APP
ng/mL
80
60
40
20
0
p<0.001
***
p<0.001
***
HC
COvax
C19
COvax
C19
Follow-up
B
Cathepsin L
ng/mL
6
4
2
0
p=0.003
HC
COvax
C19
COvax
C19
Follow-up
C
PZP
ng/mL
250
200
150
100
50
0
**
*
*
*
HC
COvax
C19
COvax
C19
Follow-up
D
SAA1
ng/mL
10^4
10^3
10^2
10^1
10^0
10^{-1}
HC
COvax
C19
COvax
C19
Follow-up


APP
Symptoms
no
yes
p=0.013
ng/mL
50
40
30
20
10
0
COvax
C19
COvax
C19
Cognitive symptoms
Fatigue


secretase
sAPP
Neuron
Aβ peptide
PZP
Amyloid plaques
Reactive astrocytes
Activated microglia